Document is current

Article History

Accepted: 5 December 2021

First Online: 21 January 2022

Declarations

:

: This study was funded by Novo Nordisk A/S, Denmark.

: Björn Eliasson reports personal fees (expert panels, lectures) from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, NovoNordisk and RLS Global, and grants and personal fees from Sanofi, all outside the submitted work. Åsa Ericsson and Barrie Chubb are employees and shareholders of Novo Nordisk A/S. Adam Fridhammar, Andreas Nilsson and Sofie Persson are employees of the Swedish Institute for Health Economics, which provides consulting services for governmental bodies, academic institutions and commercial life science enterprises (including Novo Nordisk A/S).

: Data will be shared with researchers who submit a research proposal approved by an independent review board. Access request proposals can be found at novonordisk-trials.com. Data will be made available after research completion and approval of the product and product use in the EU and the US. Individual participant data will be shared in datasets in a de-identified and anonymised format. There will not be any limitations on how these data can be used.

: The economic model (IHE-DCM) used in this study is proprietary intellectual property. For access, please contact Sofie Persson at IHE (sofie.persson@ihe.se).

: All authors contributed to the design of the study. AF, AN and SP conducted the analyses. All authors contributed to the interpretation of the results and the creation of this manuscript.

: Not applicable.

: Not applicable.

: Not applicable.